Health Care • Other Pharmaceuticals
$330.84 ▲ +0.31
(+0.09%)
MKT CAP: $63.07B • VOL: 1.35M
52W L $245 52W H $378
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$278
MEDIAN
$371
MEAN
$377
HIGH
$450
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE COR TAPE
COR // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $400.32 | $380.47 | 2025-02-14 | $301.06 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $416.86 | $390.39 | 2025-02-06 | $310.99 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $377.16 | $363.92 | 2025-01-29 | $317.61 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $337.46 | — | 2025-01-17 | $324.22 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $291.14 | $314.30 | 2025-01-09 | $294.45 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $393.70 | $344.07 | 2024-12-18 | $287.83 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $320.91 | $334.15 | 2024-12-04 | $307.68 | -4.3% | 48% | C |